BCM
RXST icon

BluePath Capital Management’s RxSight RXST Stock Holding History

BluePath Capital Management’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,135
Closed -$31.7K – 280
2023
Q3 		$31.7K Buy
+1,135
New +$33.8K 0.03% 260

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BluePath Capital Management's RXST Position: Q4 2023 in Review

BluePath Capital Management sold out of RxSight (RXST) in Q4 2023, closing a stake of 1,135 shares — an estimated $31.7K sold.

BluePath Capital Management first reported a position in RXST in Q3 2023 and held it in 1 quarter. The position peaked at $31.7K in Q3 2023. 169 funds tracked by Wall St. Rank hold RXST as of Q4 2023.

  • BluePath Capital Management reported no remaining RxSight position as of Q4 2023 after selling out during the quarter.
  • BluePath Capital Management sold 1,135 RxSight shares in Q4 2023, an estimated $31.7K.
  • BluePath Capital Management first reported a position in RxSight in Q3 2023 and held it in 1 quarter.
  • BluePath Capital Management's RxSight position peaked at $31.7K in Q3 2023.
  • 169 funds tracked by Wall St. Rank held RxSight as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.